» Articles » PMID: 32667925

IDrug: Integration of Drug Repositioning and Drug-target Prediction Via Cross-network Embedding

Overview
Specialty Biology
Date 2020 Jul 16
PMID 32667925
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Computational drug repositioning and drug-target prediction have become essential tasks in the early stage of drug discovery. In previous studies, these two tasks have often been considered separately. However, the entities studied in these two tasks (i.e., drugs, targets, and diseases) are inherently related. On one hand, drugs interact with targets in cells to modulate target activities, which in turn alter biological pathways to promote healthy functions and to treat diseases. On the other hand, both drug repositioning and drug-target prediction involve the same drug feature space, which naturally connects these two problems and the two domains (diseases and targets). By using the wisdom of the crowds, it is possible to transfer knowledge from one of the domains to the other. The existence of relationships among drug-target-disease motivates us to jointly consider drug repositioning and drug-target prediction in drug discovery. In this paper, we present a novel approach called iDrug, which seamlessly integrates drug repositioning and drug-target prediction into one coherent model via cross-network embedding. In particular, we provide a principled way to transfer knowledge from these two domains and to enhance prediction performance for both tasks. Using real-world datasets, we demonstrate that iDrug achieves superior performance on both learning tasks compared to several state-of-the-art approaches. Our code and datasets are available at: https://github.com/Case-esaC/iDrug.

Citing Articles

Improving drug repositioning accuracy using non-negative matrix tri-factorization.

Li Q, Wang Y, Wang J, Zhao C Sci Rep. 2025; 15(1):7840.

PMID: 40050702 PMC: 11885831. DOI: 10.1038/s41598-025-91757-8.


Artificial Intelligence in Natural Product Drug Discovery: Current Applications and Future Perspectives.

Gangwal A, Lavecchia A J Med Chem. 2025; 68(4):3948-3969.

PMID: 39916476 PMC: 11874025. DOI: 10.1021/acs.jmedchem.4c01257.


Improving drug repositioning with negative data labeling using large language models.

Picard M, Leclercq M, Bodein A, Scott-Boyer M, Perin O, Droit A J Cheminform. 2025; 17(1):16.

PMID: 39905466 PMC: 11796214. DOI: 10.1186/s13321-025-00962-0.


Compound-protein interaction prediction based on heterogeneous network reveals potential antihepatoma agents.

Wang Y, Li T, Chen J iScience. 2024; 27(8):110418.

PMID: 39108729 PMC: 11301071. DOI: 10.1016/j.isci.2024.110418.


A comparative benchmarking and evaluation framework for heterogeneous network-based drug repositioning methods.

Li Y, Yang Y, Tong Z, Wang Y, Mi Q, Bai M Brief Bioinform. 2024; 25(3).

PMID: 38647153 PMC: 11033846. DOI: 10.1093/bib/bbae172.


References
1.
Cheng F, Kovacs I, Barabasi A . Network-based prediction of drug combinations. Nat Commun. 2019; 10(1):1197. PMC: 6416394. DOI: 10.1038/s41467-019-09186-x. View

2.
Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View

3.
Li J, Zheng S, Chen B, Butte A, Swamidass S, Lu Z . A survey of current trends in computational drug repositioning. Brief Bioinform. 2015; 17(1):2-12. PMC: 4719067. DOI: 10.1093/bib/bbv020. View

4.
Lim H, Poleksic A, Yao Y, Tong H, He D, Zhuang L . Large-Scale Off-Target Identification Using Fast and Accurate Dual Regularized One-Class Collaborative Filtering and Its Application to Drug Repurposing. PLoS Comput Biol. 2016; 12(10):e1005135. PMC: 5055357. DOI: 10.1371/journal.pcbi.1005135. View

5.
Himmelstein D, Lizee A, Hessler C, Brueggeman L, Chen S, Hadley D . Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife. 2017; 6. PMC: 5640425. DOI: 10.7554/eLife.26726. View